POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma

BACKGROUND: Squamous carcinoma of the anal canal (SCAC) is a human papillomavirus (HPV)-driven cancer with poor prognosis in locally advanced or recurrent settings. Carboplatin–paclitaxel is the preferred first-line regimen for unresectable locally advanced or metastatic SCAC, with the reported medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Sheela, Jones, Mark, Bowman, Jill, Tian, Chuan, Spano, Jean-Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449327/
https://www.ncbi.nlm.nih.gov/pubmed/36091159
http://dx.doi.org/10.3389/fonc.2022.935383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449327/
https://www.ncbi.nlm.nih.gov/pubmed/36091159
http://dx.doi.org/10.3389/fonc.2022.935383

Ejemplares similares